Item 7.01 Regulation FD Disclosure.

Aquestive Therapeutics, Inc. (the "Company") is furnishing this Current Report on Form 8-K in connection with the disclosure of information, in the form of an investor presentation, to be given at meetings with institutional investors, analysts and others (the "Investor Presentation"). This information may be amended or updated at any time and from time to time through another Current Report on Form 8-K, a later Company filing or other means. A copy of the Company's Investor Presentation is attached hereto as Exhibit 99.1 to this Current Report on Form 8-K and incorporated into this Item 7.01 by reference and replaces in its entirety all prior investor presentations filed by the Company.

The information in this Item 7.01 (including Exhibit 99.1) shall not be deemed to be "filed" for purposes of, or otherwise subject to the liabilities of, Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), nor shall it be deemed to be incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in any such filing.

Item 8.01 Other Events.

On September 27, 2022, the Company issued a press release announcing its positive EPIPHAST II Trial Data for AQST-109. A copy of the Company's press release is attached hereto as Exhibit 99.2 and incorporated into this Item 8.01 by reference.




Item 9.01   Financial Statements and Exhibits.



(d)Exhibits.

Exhibit               Description
Number

  99.1                Investor Presentation dated September 2022.
  99.2                Press Release dated September 27, 2022 announcing the Company's positive
                      EPIPHAST II Trial Data for AQST-109.

© Edgar Online, source Glimpses